A recent article by James Stansbury discusses the overlooked potential of ivermectin (IVM), a drug commonly known as a horse dewormer, to treat various types of cancer. Despite its cheap cost and safety, it has been largely dismissed by the medical community and media, possibly due to biases formed during the COVID-19 pandemic.
1. Rejection of Ivermectin: During the COVID-19 pandemic, IVM faced heavy criticism and was banned as a treatment by the FDA and CDC in the U. S. In contrast, India reportedly experienced significantly lower COVID-19 death rates while using it.
2. Formation of FLCCC: After facing backlash, some doctors formed the Front Line Covid-19 Critical Care Alliance (FLCCC) to explore and support the use of IVM and other repurposed drugs for COVID-19 treatment.
3. Expansion to Cancer Research: In 2024, the FLCCC began exploring IVM as a potential cancer treatment, highlighted by Dr. Kathleen Ruddy's case of a patient with late-stage prostate cancer who improved after using IVM.
4. Pharmaceutical Industry Resistance: Dr. Ruddy indicated that the pharmaceutical industry is unlikely to invest in a drug that is very inexpensive, thereby contributing to the neglect of IVM as a cancer treatment.
5. Independent Medical Alliance (IMA): The FLCCC evolved into the Independent Medical Alliance, focusing on patient-centered care and offering new protocols. They provide research on IVM and other drugs that show promise in fighting cancer.
6. Cancer Stem Cells (CSCs): The IMA’s resource material explains that traditional cancer treatments often ignore cancer stem cells, which can survive and lead to disease recurrence. IVM and similar drugs may effectively target these CSCs.
7. Personalized Treatment Plans: The IMA advocates for individualized treatment plans based on cancer type and patient characteristics and offers a comprehensive Cancer Care Guide outlining various repurposed drugs.
8. Guidelines for Usage: The IMA advises patients to undergo treatment under professional supervision, as cancer treatment can be complex and individualized.
9. Lack of Official Approval: Currently, there are no FDA or CDC endorsements for using IVM in cancer treatment, potentially limiting its availability through traditional oncologists.
The article raises significant questions about conventional cancer treatment approaches and the potential of inexpensive alternatives like IVM. The focus on cancer stem cells and the development of personalized protocols through organizations like the IMA may offer new hope for cancer patients. However, caution is advised as these treatments have not received official approval, and medical supervision is mandatory.
No comments:
Post a Comment